​

Teladoc Health (TDOC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TDOC Stock Forecast

Teladoc Health stock forecast is as follows: an average price target of $11.00 (represents a 16.53% upside from TDOC’s last price of $9.44) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.

TDOC Price Target

The average price target for Teladoc Health (TDOC) is $11.00 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $9.00. This represents a potential 16.53% upside from TDOC's last price of $9.44.

TDOC Analyst Ratings

Buy

According to 22 Wall Street analysts, Teladoc Health's rating consensus is 'Buy'. The analyst rating breakdown for TDOC stock is 0 'Strong Buy' (0.00%), 11 'Buy' (50.00%), 11 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Teladoc Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 04, 2024Jessica TassanPiper Sandler$13.00$11.0118.07%37.71%
Oct 31, 2024Daniel GrosslightCitigroup$11.00$8.8624.15%16.53%
Oct 30, 2024Elizabeth AndersonEvercore ISI$9.00$8.861.58%-4.66%
Aug 06, 2024Jessica TassanPiper Sandler$10.00$7.6031.58%5.93%
Jun 11, 2024Steve ValiquetteBarclays$20.00$10.4890.75%111.86%
May 31, 2024Glen SantangeloJefferies$10.00$11.29-11.43%5.93%
May 20, 2024Glen SantangeloJefferies$14.00$12.3912.99%48.31%
Apr 05, 2024George HillDeutsche Bank$18.00$14.6422.91%90.68%
Apr 12, 2023Jeff GarroStephens$25.00$25.86-3.33%164.83%
Dec 13, 2022Citigroup$33.00$27.6319.44%249.58%
Sep 28, 2022RBC Capital$35.00$27.5227.18%270.76%
Sep 27, 2022Deutsche Bank$31.00$26.3717.56%228.39%
Jul 31, 2022Steve ValiquetteBarclays$42.00$36.8513.98%344.92%
Jul 28, 2022Barclays$40.00$33.8218.27%323.73%
Jul 28, 2022Oppenheimer$55.00$43.2427.20%482.63%
Jul 28, 2022Jessica TassanPiper Sandler$40.00$43.24-7.49%323.73%
Jul 28, 2022Elizabeth Anderson CFAEvercore ISI$28.00$43.24-35.25%196.61%
Jun 29, 2022Stifel Nicolaus$36.00$34.344.83%281.36%
May 26, 2022Goldman Sachs$55.00$33.5863.80%482.63%
May 18, 2022Jessica TassanPiper Sandler$42.00$32.8527.85%344.92%
Apr 28, 2022Craig-Hallum$30.00$33.77-11.16%217.80%
Apr 28, 2022Canaccord Genuity$50.00$33.7848.02%429.66%
Apr 28, 2022Deutsche Bank$44.00$33.8430.02%366.10%
Apr 28, 2022RBC Capital$65.00$29.38121.24%588.56%
Apr 28, 2022Citigroup$43.00$29.3046.76%355.51%
Apr 28, 2022Credit Suisse$35.00$55.99-37.49%270.76%
Apr 28, 2022Needham$48.00$55.99-14.27%408.47%
Apr 28, 2022Leerink Partners$35.00$55.99-37.49%270.76%
Apr 28, 2022Sean DodgeRBC Capital$65.00$33.5193.97%588.56%
Apr 28, 2022Stan BerenshteynWells Fargo$40.00$33.5119.37%323.73%
Apr 28, 2022Elizabeth Anderson CFAEvercore ISI$30.00$33.51-10.47%217.80%
Apr 28, 2022Stephanie DavisLeerink Partners$35.00$33.514.45%270.76%
Apr 28, 2022Steven ValiquetteBarclays$45.00$33.5134.29%376.69%
Apr 28, 2022Jonathan YongCredit Suisse$35.00$33.514.45%270.76%
Apr 27, 2022Vikram KesavabhotlaRobert W. Baird$38.00$55.99-32.13%302.54%
Mar 19, 2022Charles RhyeeCowen & Co.$94.00$68.9636.31%895.76%
Feb 28, 2022Dev WeerasuriyaBerenberg Bank$141.00$75.9185.75%1393.64%
Feb 28, 2022Glen SantangeloJefferies$82.00$75.918.02%768.64%
Feb 23, 2022Michael WiederhornOppenheimer$130.00$61.46111.52%1277.12%
Feb 23, 2022Ryan MacDonaldNeedham$100.00$61.4662.71%959.32%
Feb 23, 2022Lisa GillJ.P. Morgan$125.00$61.46103.38%1224.15%
Feb 23, 2022Matt HewittCraig-Hallum$67.00$61.469.01%609.75%
Feb 23, 2022Steven ValiquetteBarclays$77.00$61.4625.28%715.68%
Feb 23, 2022Vikram KesavabhotlaRobert W. Baird$72.00$61.4617.15%662.71%
Feb 23, 2022Elizabeth Anderson CFAEvercore ISI$70.00$61.4613.90%641.53%
Feb 23, 2022David GrossmanStifel Nicolaus$74.00$61.4620.40%683.90%
Feb 23, 2022Donald HookerKeyBanc$100.00$61.4662.71%959.32%
Feb 23, 2022Richard CloseCanaccord Genuity$112.00$61.4682.23%1086.44%
Jan 06, 2022Steve BaxterWells Fargo$121.00$81.7647.99%1181.78%
Nov 19, 2021Jacob JohnsonStephens$135.00$116.9915.39%1330.08%
Oct 28, 2021Steven HalperCantor Fitzgerald$150.00$149.180.55%1488.98%

The latest Teladoc Health stock forecast, released on Dec 04, 2024 by Jessica Tassan from Piper Sandler, set a price target of $13.00, which represents a 18.07% increase from the stock price at the time of the forecast ($11.01), and a 37.71% increase from TDOC last price ($9.44).

Teladoc Health Price Target by Period

1M3M12M
# Anlaysts138
Avg Price Target$13.00$11.00$13.13
Last Closing Price$9.44$9.44$9.44
Upside/Downside37.71%16.53%39.09%

In the current month, the average price target of Teladoc Health stock is $13.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 37.71% increase as opposed to Teladoc Health's last price of $9.44. This month's average price target is up 18.18% compared to last quarter, and down -0.99% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 04, 2024Piper SandlerOverweightOverweightHold
Oct 31, 2024Cowen & Co.HoldHoldHold
Oct 31, 2024BarclaysOverweightOverweightHold
Oct 31, 2024CitigroupNeutralNeutralHold
Oct 09, 2024RBC CapitalOutperformOutperformHold
Oct 08, 2024RBC CapitalBuyBuyHold
Oct 08, 2024Evercore ISIOutperformOutperformHold
Sep 17, 2024RBC CapitalBuyBuyHold
Sep 17, 2024Piper SandlerUnderperformUnderperformHold
Sep 17, 2024JefferiesBuyBuyHold
Sep 17, 2024JefferiesHoldHoldHold
Aug 20, 2024Piper SandlerBuyBuyHold
Aug 20, 2024OppenheimerUnderperformUnderperformHold
Aug 06, 2024Piper SandlerMixedMixedHold
Aug 06, 2024Piper SandlerOverweightOverweightHold
Jun 11, 2024BarclaysOverweightOverweightHold
Jun 11, 2024Bank of America SecuritiesNeutralNeutralHold
Jun 10, 2024CitigroupNeutralNeutralHold
May 20, 2024JefferiesHoldHoldHold
May 14, 2024Bank of America SecuritiesNeutralNeutralHold
Apr 23, 2024CitigroupNeutralNeutralHold
Apr 05, 2024Deutsche BankHoldHoldHold
Feb 21, 2024RBC CapitalOutperformOutperformHold
Oct 20, 2023CitigroupNeutralNeutralHold
Jul 26, 2023NeedhamHoldHoldHold
Apr 12, 2023StephensEqual-WeightInitialise
Mar 06, 2023Wells FargoEqual-WeightEqual-WeightHold
Feb 23, 2023SVB LeerinkMarket PerformOutperformUpgrade
Dec 13, 2022CitigroupNeutralNeutralHold
Oct 24, 2022Piper SandlerBuyNeutralDowngrade
Oct 24, 2022GuggenheimSellBuyUpgrade
Oct 24, 2022JefferiesHoldUnderperformDowngrade
Oct 24, 2022BarclaysEqual-WeightUnderweightDowngrade
Oct 24, 2022BMO CapitalMarket PerformDowngrade
Sep 28, 2022RBC CapitalOutperformOutperformHold
Sep 27, 2022Deutsche BankHoldHoldHold
Aug 17, 2022GuggenheimNeutralSellDowngrade
Aug 12, 2022D.A. DavidsonBuyInitialise
Aug 02, 2022Cowen & Co.Market PerformDowngrade
Jul 28, 2022OppenheimerOutperformOutperformHold
Jul 20, 2022BarclaysEqual-WeightEqual-WeightHold
Jul 18, 2022JefferiesHoldHoldHold
May 26, 2022Goldman SachsBuyBuyHold
May 18, 2022Piper SandlerBuyBuyHold
Apr 28, 2022Craig-HallumHoldHoldHold
Apr 28, 2022Canaccord GenuityBuyBuyHold
Apr 28, 2022Deutsche BankHoldHoldHold
Apr 28, 2022RBC CapitalOutperformOutperformHold
Apr 28, 2022Wells FargoEqual-WeightOverweightDowngrade
Apr 28, 2022GuggenheimNeutralDowngrade
Apr 28, 2022CitigroupNeutralDowngrade
Apr 28, 2022Wells FargoEqual-WeightDowngrade
Apr 28, 2022Credit SuisseOutperformNeutralDowngrade
Apr 28, 2022NeedhamBuyBuyHold
Apr 28, 2022SVB LeerinkOutperformMarket PerformDowngrade
Apr 28, 2022William BlairMarket PerformDowngrade
Feb 25, 2022Credit SuisseOutperformOutperformHold
Feb 24, 2022Deutsche BankHoldHoldHold
Feb 23, 2022KeyBancOverweightOverweightHold
Feb 23, 2022OppenheimerOutperformOutperformHold
Feb 23, 2022Craig-HallumHoldHoldHold
Feb 23, 2022NeedhamBuyBuyHold
Feb 23, 2022BarclaysEqual-WeightEqual-WeightHold
Feb 23, 2022SVB LeerinkOutperformOutperformHold
Feb 08, 2022JefferiesHoldHoldHold
Jan 11, 2022Piper SandlerOverweightOverweightHold

Teladoc Health's last stock rating was published by Piper Sandler on Dec 04, 2024. The company gave TDOC a "Overweight" rating, the same as its previous rate.

Teladoc Health Financial Forecast

Teladoc Health Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-----------------$660.24M$652.41M$629.24M$637.71M$611.40M$592.38M$565.35M$554.24M$521.66M$503.14M$453.68M$383.32M$288.81M
Avg Forecast$786.92M$768.01M$752.18M$735.73M$653.50M$645.80M$642.65M$641.61M$638.22M$633.91M$631.62M$632.60M$639.33M$631.18M$649.16M$637.31M$670.81M$663.54M$649.18M$619.30M$633.40M$608.89M$586.74M$568.68M$547.17M$516.63M$500.60M$451.91M$378.93M$282.18M
High Forecast$820.26M$800.55M$784.05M$766.90M$681.19M$673.16M$669.88M$668.79M$665.26M$660.77M$658.38M$656.59M$674.83M$631.48M$649.33M$637.31M$675.14M$674.54M$676.69M$645.54M$660.24M$608.89M$586.74M$568.68M$547.17M$516.63M$500.60M$451.91M$378.93M$282.18M
Low Forecast$762.68M$744.36M$729.01M$713.07M$633.37M$625.90M$622.85M$621.84M$618.56M$614.39M$612.16M$609.34M$617.33M$630.87M$649.00M$637.31M$667.50M$656.16M$629.19M$600.22M$613.89M$608.89M$586.74M$568.68M$547.17M$516.63M$500.60M$451.91M$378.93M$282.18M
# Analysts66669999555121715510112211111610101811132111153
Surprise %-----------------1.00%1.00%1.02%1.01%1.00%1.01%0.99%1.01%1.01%1.01%1.00%1.01%1.02%

Teladoc Health's average Quarter revenue forecast for Dec 23 based on 11 analysts is $670.81M, with a low forecast of $667.50M, and a high forecast of $675.14M. TDOC's average Quarter revenue forecast represents a 1.60% increase compared to the company's last Quarter revenue of $660.24M (Sep 23).

Teladoc Health EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts66669999555121715510112211111610101811132111153
EBITDA-----------------$40.39M$31.15M$24.51M$3.83B$-6.27M$-1.97M$-1.27M$19.75M$-1.54M$-12.22M$-20.27M$-360.90M$18.60M
Avg Forecast$-229.44M$-223.93M$-219.31M$-214.52M$-190.54M$-188.30M$-187.38M$-187.07M$-186.09M$-184.83M$-184.16M$-184.45M$-186.41M$-184.03M$-189.28M$-375.52B$-195.59M$-193.47M$-189.28M$-401.62B$28.17M$85.70M$82.58M$-429.54B$77.01M$72.71M$70.46M$-35.76M$53.33M$39.71M
High Forecast$-222.38M$-217.03M$-212.56M$-207.91M$-184.67M$-182.50M$-181.61M$-181.31M$-180.35M$-179.14M$-178.49M$-177.67M$-179.99M$-183.94M$-189.23M$-300.41B$-194.62M$-191.32M$-183.45M$-321.30B$33.80M$85.70M$82.58M$-343.63B$77.01M$72.71M$70.46M$-28.61M$53.33M$39.71M
Low Forecast$-239.16M$-233.42M$-228.61M$-223.61M$-198.61M$-196.27M$-195.32M$-195.00M$-193.97M$-192.66M$-191.96M$-191.44M$-196.76M$-184.12M$-189.32M$-450.62B$-196.85M$-196.68M$-197.30M$-481.94B$22.53M$85.70M$82.58M$-515.45B$77.01M$72.71M$70.46M$-42.91M$53.33M$39.71M
Surprise %------------------0.21%-0.16%-0.00%135.96%-0.07%-0.02%0.00%0.26%-0.02%-0.17%0.57%-6.77%0.47%

11 analysts predict TDOC's average Quarter EBITDA for Dec 23 to be $-195.59M, with a high of $-194.62M and a low of $-196.85M. This is -584.24% lower than Teladoc Health's previous annual EBITDA (Sep 23) of $40.39M.

Teladoc Health Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts66669999555121715510112211111610101811132111153
Net Income-----------------$-57.07M$-65.18M$-69.23M$-3.81B$-73.48M$-3.10B$-6.67B$-10.98M$-84.34M$-133.82M$-199.65M$-393.97M$-35.88M
Avg Forecast$30.87M$-17.15M$-34.30M$-46.30M$-33.79M$-41.84M$-44.97M$-59.27M$-24.15M$-36.20M$-39.18M$-53.35M$-39.29M$-47.50M$-59.10M$-379.42B$-37.61M$-62.51M$-69.71M$-405.80B$-20.39M$-96.25M$-104.02M$-434.01B$-96.73M$-114.37M$-89.96M$-187.60M$-44.23M$-54.76M
High Forecast$32.57M$-16.46M$-32.93M$-44.45M$-32.44M$-40.17M$-43.17M$-56.90M$-23.18M$-34.75M$-37.61M$-32.01M$-5.89M$-45.60M$-56.73M$-303.54B$27.35M$-45.62M$-66.91M$-324.64B$-16.31M$-96.25M$-104.02M$-347.21B$-96.73M$-114.37M$-89.96M$-150.08M$-44.23M$-54.76M
Low Forecast$29.63M$-18.09M$-36.19M$-48.85M$-35.65M$-44.15M$-47.45M$-62.53M$-25.48M$-38.19M$-41.33M$-65.54M$-55.01M$-50.11M$-62.35M$-455.31B$-49.57M$-77.72M$-73.55M$-486.96B$-24.47M$-96.25M$-104.02M$-520.81B$-96.73M$-114.37M$-89.96M$-225.12M$-44.23M$-54.76M
Surprise %-----------------0.91%0.94%0.00%186.85%0.76%29.82%0.02%0.11%0.74%1.49%1.06%8.91%0.66%

Teladoc Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TDOC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Teladoc Health SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts66669999555121715510112211111610101811132111153
SG&A-----------------$301.87M$358.13M$345.43M$322.57M$346.10M$333.37M$296.85M$290.92M$276.70M$278.29M$259.40M$531.68M$135.53M
Avg Forecast$477.35M$465.88M$456.28M$446.30M$396.42M$391.74M$389.84M$389.20M$387.15M$384.54M$383.14M$383.74M$387.82M$382.88M$393.79M$386.60M$406.92M$402.50M$393.80M$375.67M$540.02M$369.36M$355.92M$344.96M$331.91M$313.39M$303.67M$243.75M$229.86M$171.17M
High Forecast$497.57M$485.62M$475.61M$465.21M$413.21M$408.34M$406.35M$405.69M$403.55M$400.83M$399.38M$398.29M$409.36M$383.06M$393.88M$386.60M$409.54M$409.18M$410.48M$391.59M$648.03M$369.36M$355.92M$344.96M$331.91M$313.39M$303.67M$292.50M$229.86M$171.17M
Low Forecast$462.65M$451.53M$442.22M$432.55M$384.21M$379.68M$377.83M$377.21M$375.22M$372.69M$371.34M$369.63M$374.47M$382.69M$393.69M$386.60M$404.91M$398.03M$381.67M$364.10M$432.02M$369.36M$355.92M$344.96M$331.91M$313.39M$303.67M$195.00M$229.86M$171.17M
Surprise %-----------------0.75%0.91%0.92%0.60%0.94%0.94%0.86%0.88%0.88%0.92%1.06%2.31%0.79%

Teladoc Health's average Quarter SG&A projection for Dec 23 is $406.92M, based on 11 Wall Street analysts, with a range of $404.91M to $409.54M. The forecast indicates a 34.80% rise compared to TDOC last annual SG&A of $301.87M (Sep 23).

Teladoc Health EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts66669999555121715510112211111610101811132111153
EPS-----------------$-0.35$-0.40$-0.42$-23.49$-0.45$-19.22$-41.58$-0.07$-0.53$-0.86$-1.31$-3.07$-0.43
Avg Forecast$0.18$-0.10$-0.20$-0.27$-0.20$-0.24$-0.26$-0.35$-0.14$-0.21$-0.23$-0.31$-0.23$-0.28$-0.34$-0.46$-0.22$-0.36$-0.41$-0.48$-0.25$-0.57$-0.61$-0.60$-0.57$-0.67$-0.53$-0.54$-0.26$-0.32
High Forecast$0.19$-0.10$-0.19$-0.26$-0.19$-0.23$-0.25$-0.33$-0.14$-0.20$-0.22$-0.19$-0.03$-0.27$-0.33$-0.44$0.16$-0.27$-0.39$-0.46$-0.24$-0.57$-0.61$-0.60$-0.57$-0.67$-0.53$-0.54$-0.26$-0.32
Low Forecast$0.17$-0.11$-0.21$-0.28$-0.21$-0.26$-0.28$-0.36$-0.15$-0.22$-0.24$-0.38$-0.32$-0.29$-0.36$-0.48$-0.29$-0.45$-0.43$-0.51$-0.26$-0.57$-0.61$-0.60$-0.57$-0.67$-0.53$-0.54$-0.26$-0.32
Surprise %-----------------0.96%0.98%0.87%95.51%0.80%31.46%69.43%0.12%0.79%1.63%2.42%11.82%1.34%

According to undefined Wall Street analysts, Teladoc Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TDOC previous annual EPS of $NaN (undefined).

Teladoc Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GDRXGoodRx$4.46$14.57226.68%Buy
ACCDAccolade$3.40$8.08137.65%Buy
TXG10x Genomics$14.72$31.75115.69%Hold
PGNYProgyny$14.74$22.6753.80%Hold
SDGRSchrödinger$21.36$28.5033.43%Buy
GEHCGE HealthCare$79.25$92.0016.09%Buy
TDOCTeladoc Health$10.07$11.009.24%Buy
VEEVVeeva Systems$226.41$235.504.01%Buy
DOCSDoximity$52.70$53.381.29%Buy
TALKTalkspace$3.26$2.50-23.31%Hold

TDOC Forecast FAQ

Is Teladoc Health a good buy?

Yes, according to 22 Wall Street analysts, Teladoc Health (TDOC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 50.00% of TDOC's total ratings.

What is TDOC's price target?

Teladoc Health (TDOC) average price target is $11 with a range of $9 to $13, implying a 16.53% from its last price of $9.44. The data is based on 22 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Teladoc Health stock go up soon?

According to Wall Street analysts' prediction for TDOC stock, the company can go up by 16.53% (from the last price of $9.44 to the average price target of $11), up by 37.71% based on the highest stock price target, and down by -4.66% based on the lowest stock price target.

Can Teladoc Health stock reach $14?

TDOC's average twelve months analyst stock price target of $11 does not support the claim that Teladoc Health can reach $14 in the near future.

What is Teladoc Health's current price target trend?

1 Wall Street analyst forecast a $13 price target for Teladoc Health (TDOC) this month, up 37.71% from its last price of $9.44. Compared to the last 3 and 12 months, the average price target increased by 16.53% and increased by 39.09%, respectively.

What are Teladoc Health's analysts' financial forecasts?

Teladoc Health's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.58B (high $2.69B, low $2.5B), average EBITDA is $-753M (high $-730M, low $-785M), average net income is $-180M (high $-173M, low $-190M), average SG&A $1.57B (high $1.63B, low $1.52B), and average EPS is $-1.049 (high $-1.007, low $-1.107). TDOC's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $3.04B (high $3.17B, low $2.95B), average EBITDA is $-887M (high $-860M, low $-925M), average net income is $-66.884M (high $-61.27M, low $-73.505M), average SG&A $1.85B (high $1.92B, low $1.79B), and average EPS is $-0.39 (high $-0.357, low $-0.429).

Did the TDOC's actual financial results beat the analysts' financial forecasts?

Based on Teladoc Health's last annual report (Dec 2022), the company's revenue was $2.41B, beating the average analysts forecast of $2.4B by 0.38%. Apple's EBITDA was $13.47B, missing the average prediction of $-429B by -103.14%. The company's net income was $-13.66B, missing the average estimation of $-434B by -96.85%. Apple's SG&A was $1.3B, missing the average forecast of $1.61B by -19.23%. Lastly, the company's EPS was $-84.6, beating the average prediction of $-2.021 by 4085.59%. In terms of the last quarterly report (Sep 2023), Teladoc Health's revenue was $660.24M, missing the average analysts' forecast of $663.54M by -0.50%. The company's EBITDA was $40.39M, missing the average prediction of $-193M by -120.88%. Teladoc Health's net income was $-57.073M, missing the average estimation of $-62.512M by -8.70%. The company's SG&A was $301.87M, missing the average forecast of $402.5M by -25.00%. Lastly, the company's EPS was $-0.35, missing the average prediction of $-0.365 by -3.98%